HSP90 inhibitors for cancer therapy and overcoming drug resistance
about
sameAs
Ganetespib: research and clinical developmentFunctions of the Hsp90 chaperone system: lifting client proteins to new heightsRaf-interactome in tuning the complexity and diversity of Raf function.Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapiesNovel therapies for myelofibrosisIdentification of two novel HSP90 proteins in Babesia orientalis: molecular characterization, and computational analyses of their structure, function, antigenicity and inhibitor interaction.Integrative quantitative proteomics unveils proteostasis imbalance in human hepatocellular carcinoma developed on nonfibrotic livers.Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide.Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsThe spectral properties of (-)-epigallocatechin 3-O-gallate (EGCG) fluorescence in different solvents: dependence on solvent polarity17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway.The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas.The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cellsIn vitro and in vivo anti-malarial activity of novel harmine-analog heat shock protein 90 inhibitors: a possible partner for artemisinin.Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.Genomic instability and colon carcinogenesis: from the perspective of genes.Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerChemically accessible hsp90 inhibitor that does not induce a heat shock responseIdentification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors.HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.Construction and in vitro/in vivo evaluation of 17-allylamino-17-demethoxygeldanamycin (17AAG)-loaded PEGylated nanostructured lipid carriers.
P2860
Q26798645-3D590018-EFDF-4D49-B102-FA8E6D17324CQ27024085-D9BDA1AA-69BF-4630-A653-FCC4EDF4F117Q27692653-EC5F306E-F8FF-45AC-B5D1-E47677CA97C6Q27853149-FEC1DC29-AC2C-45B2-B0FB-F771794CDC04Q28081693-F3978A5A-3FA8-4CA0-9B13-70FE28FC7E79Q30364037-555796D7-54BC-4D9A-89D3-C2D21E10F8ACQ30397531-71224A66-28C6-455B-BEF1-941F8939D350Q31140123-F4D642A7-76A8-4E65-AC40-3E31BBAA2017Q34120364-7D8D087A-3E20-4D1A-AE2B-67AB09F257F0Q34129993-1165C648-8BEC-4BAA-B478-60A5EE518A06Q34164027-3D975E36-D862-4839-A8E9-B1D89FF9FD1DQ35053298-18CB409B-2CF2-44F7-B04A-C66DAFA46891Q35206531-6C10AE9E-0295-4D64-8069-DB65665A697BQ35336213-BFDEA953-C4E4-4086-9C33-1EBBAB982527Q35818450-0FDD98B1-BAFF-4666-B464-692627982B86Q36442900-70FA527E-26C8-41AE-AC93-0C5C8B9C95AAQ37123188-8EB51259-B4FF-4CE4-8E5D-EF95D6029424Q37460707-BED879F7-6006-46E9-B68B-404C91EB9AB7Q37554911-5FD44E36-78F8-46BD-BF65-B2CC1FEC15DAQ38111773-8CBE62CE-31BE-4054-B8E9-F398FB6924ADQ38382840-07FC73DE-F646-424E-97E9-6B084D7CA198Q38648408-6B01BB95-EBBC-456C-9CEF-F92B4D9BD883Q41863286-41AF6AE9-CF31-4941-9FB2-C9FE6B5319DCQ42434145-32500C94-02C9-4222-A611-6DC24D538F57Q42945545-E19AAC0A-77D4-4A38-A9DC-D412228AA8CBQ47269736-850454B9-B6BC-4128-9AE4-B7E27B6F7B76Q53551032-A76C8BC8-751B-4D57-899E-B5A7A94AE86D
P2860
HSP90 inhibitors for cancer therapy and overcoming drug resistance
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
HSP90 inhibitors for cancer therapy and overcoming drug resistance
@ast
HSP90 inhibitors for cancer therapy and overcoming drug resistance
@en
HSP90 inhibitors for cancer therapy and overcoming drug resistance
@nl
type
label
HSP90 inhibitors for cancer therapy and overcoming drug resistance
@ast
HSP90 inhibitors for cancer therapy and overcoming drug resistance
@en
HSP90 inhibitors for cancer therapy and overcoming drug resistance
@nl
altLabel
HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance
@en
prefLabel
HSP90 inhibitors for cancer therapy and overcoming drug resistance
@ast
HSP90 inhibitors for cancer therapy and overcoming drug resistance
@en
HSP90 inhibitors for cancer therapy and overcoming drug resistance
@nl
P1476
HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance
@en
HSP90 inhibitors for cancer therapy and overcoming drug resistance
@en
P2093
Komal Jhaveri
P304
P356
10.1016/B978-0-12-397927-8.00015-4
P407
P50
P577
2012-01-01T00:00:00Z